Physiatrist Resource Center

Members & Publications

In-Depth Resources for Physiatrists

We are supporting members by creating timely, needed resources, collaborating across health care and highlighting the best education and news that is applicable to you and your PM&R practice right now. As the primary medical specialty society for physical medicine and rehabilitation, this is your place for resources to help you today.

AAPM&R members: Even more resources are being shared between physiatrists in our Care in the Time of COVID-19 member forum on PhyzForum. Exchange important dialogue about your challenges, ask your questions and concerns as well as share resources with each other.

If you can't find what you need or would like additional support, we're here to help. Contact us at (847) 737-6000 or email

Webinar Recordings

Members: 20+ COVID-19 specific webinar recordings are now available for you to access. Thank you to our panelists and participants!

View all COVID-19 Webinars.

From the AAPM&R Board of Governors

"Our country is in the midst of a medical pandemic. The AAPM&R (Academy), including its volunteer leaders and staff, have enormous empathy for our members, their patients, and families as COVID-19 has disrupted every aspect of our personal and professional lives. Together, we need to find the resilience to persevere for our personal and our patients’ health and well-being. Together, we need to find the resilience to persevere for our personal and our patients’ health and well-being.”  Read the full statement here.

Stay Up-to-Date

U.S. House of Representatives passes HALT Fentanyl Act

Jun 1, 2023, 09:21 AM by Joy Thissen

On May 25, 2023, the U.S. House passed the Halt all Lethal Tracking of (HALT) Fentanyl Act by a bipartisan vote of 289 – 133. Under the bill, fentanyl-related substances would be automatically, and permanently placed in Schedule 1, under the Controlled Substances Act. The bill would also make changes to registration requirements for conducting research with controlled substances, including:

  • permitting a single registration for related research sites in certain circumstances,
  • waiving the requirement for a new inspection in certain situations, and
  • allowing a registered researcher to perform certain manufacturing activities with small quantities of a substance without obtaining a manufacturing registration.

The bill would also treat fentanyl-related substances by the same quantity thresholds and subject to the same penalties as offenses involving fentanyl analogues (e.g., offenses involving one hundred grams or more trigger a 10-year mandatory minimum prison term).

As the HALT Fentanyl Act is specific to fentanyl-related substances, it does not impact medical fentanyl, which is a Schedule II drug. 

The bill now heads to the Senate for further action. Members with questions about this legislation can contact